Italia markets open in 6 hours 56 minutes

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
13,19+0,11 (+0,84%)
Alla chiusura: 04:00PM EDT
13,29 +0,10 (+0,76%)
Dopo ore: 06:49PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente13,08
Aperto13,10
Denaro13,00 x 1000
Lettera13,21 x 4000
Min-Max giorno13,08 - 13,28
Intervallo di 52 settimane13,01 - 17,11
Volume1.293.552
Media Volume1.779.577
Capitalizzazione42,03B
Beta (5 anni mensile)0,54
Rapporto PE (ttm)36,64
EPS (ttm)0,36
Prossima data utili09 mag 2024
Rendimento e dividendo (futuro)0,64 (4,88%)
Data ex dividendo28 set 2023
Stima target 1A18,12
  • GlobeNewswire

    HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

    — Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“HUTCHMED”) today announced that Takeda (TSE:4502/​NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in Japan for the approval of fruquintinib for the treatment of adult patients with previously

  • GlobeNewswire

    HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

    — Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) and Takeda (TSE:4502, NYSE:TAK) today announced that results